SPY425.10+2.50 0.59%
DIA341.98+3.20 0.94%
IXIC14,369.71+97.98 0.69%

BRIEF-Inovio Announces Positive Data From Phase 2 Segment Of Clinical Trial Evaluating Ino-4800, Its Covid-19 Dna Vaccine

05/10/2021 08:03
BRIEF-Inovio Announces Positive Data From Phase 2 Segment Of Clinical Trial Evaluating Ino-4800, Its Covid-19 Dna Vaccine

- Inovio Pharmaceuticals Inc INO.O:

  • INOVIO ANNOUNCES POSITIVE DATA FROM PHASE 2 SEGMENT OF CLINICAL TRIAL EVALUATING INO-4800, ITS COVID-19 DNA VACCINE

  • INOVIO PHARMACEUTICALS INC - INO-4800 WAS SHOWN TO BE SAFE, WELL-TOLERATED AND IMMUNOGENIC IN ALL AGE GROUPS

  • INOVIO PHARMACEUTICALS INC - MAJORITY OF ADVERSE EVENTS (AES) WERE GRADE 1 AND GRADE 2 IN SEVERITY

  • INOVIO PHARMACEUTICALS INC - ADVERSE EVENTS DID NOT APPEAR TO INCREASE IN FREQUENCY WITH SECOND DOSE

  • INOVIO - GEOMETRIC MEAN FOLD RISE OF BINDING & NEUTRALIZING ANTIBODY LEVELS WERE STATISTICALLY SIGNIFICANTLY GREATER IN 2.0 MG DOSE GROUP

  • INOVIO PHARMACEUTICALS INC - T CELL IMMUNE RESPONSES MEASURED BY ELISPOT ASSAY WERE ALSO HIGHER IN 2.0 MG DOSE GROUP COMPARED TO 1.0 MG DOSE GROUP

  • INOVIO PHARMACEUTICALS - FOLLOWING SUBMISSION AND FDA CONCURRENCE TO PROCEED, COMPNY PLANS TO CONDUCT A GLOBAL PHASE 3 CLINICAL TRIAL FOR INO-4800

  • INOVIO PHARMACEUTICALS INC - PLANS TO FILE PRELIMINARY PHASE 2 RESULTS AND DEVICE DATA WITH U.S. FDA

Source text for Eikon: ID:nPn2dtcnqa

Further company coverage: INO.O


(([email protected];))